iMedicus Cardiology, presented by EOCI Pharmacomm, features short and engaging episodes for Canadian Health Care Professionals practicing in cardiology. Tune in for the latest on guidelines, current and emerging therapies, clinical pearls, and best practices, across a range of topics in Cardiology.
iMedicus Cardiology
Claim This Podcastby imedicuscardiology
5.0(1 reviews)
3 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇨🇦
Podcast Overview
iMedicus Cardiology, presented by EOCI Pharmacomm, features short and engaging episodes for Canadian Health Care Professionals practicing in cardiology. Tune in for the latest on guidelines, current and emerging therapies, clinical pearls, and best practices, across a range of topics in Cardiology.
Language
🇺🇲
Publishing Since
6/18/2021
Reach the team behind iMedicus Cardiology
Verified contact details for this show aren't on file yet — sign up to get notified when they land.
Recent Episodes
July 16, 2021
Current Challenges in Anticoagulating AF Patients with Renal Impairment
In this podcast, we are joined by Dr. Andrew Steele, nephrologist at Lakeridge Health. He discusses the efficacy and safety considerations in patients with atrial fibrillation and chronic kidney disease, Canadian recommendations for appropriate dosing of NOACs and how clinicians can limit the progression of renal impairment in their patients. This program was made available through funding from Bayer.
July 16, 2021
Updates to the CCS Dyslipidemia Guidelines: Application to Established CVD Patients
In this podcast, we are joined by Dr. Vineeta Ahooja, cardiologist in the greater Toronto area at the Heart Health Institute, and Dr. George Thanassoulis, cardiologist at McGill University Health Centre and Co-Chair of the 2021 Canadian Cardiovascular Society Dyslipidemia Guidelines. They discuss the use of ezetimibe and PCSK9i, including considerations around the costs of medications. When triglycerides are high, should icosapent ethyl or PCSK9i be considered first? Listen to find out! This program was made available through funding from HLS Therapeutics.
June 18, 2021
Current Dyslipidemia Management: What do the 2021 CCS Guidelines Say?
Welcome to the podcast series CAN-R3: Canadian Initiative to Reduce Residual Risk – Game Changers in Dyslipidemia Management. In this series, Canadian experts discuss the importance and challenges of reducing LDL-C in patients with established ASCVD, recommendations from the 2021 Canadian Cardiovascular Society Guidelines, and evidence around statins efficacy and adherence in different patient populations. Visit iMedicus.ca/Dyslipidemia to watch the Section 1 accredited webinars. In this first episode, Dr. Judy Luu and Dr. Shaun Goodman exchange on the different contributors to residual risk, the role of LDL-C in atherosclerosis, the importance of reducing LDL-C as low as possible, identifying patients who benefit the most from intensification therapy beyond statins, and the shift to LDL-C thresholds as opposed to treatment targets.
3 total episodes available with 1 transcripts
Deep-dive analytics for iMedicus Cardiology
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is iMedicus Cardiology?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.